Abstract
Introduction: Severe asthma leads to low quality of life and high costs to the economy of the country. Although omalizumab is well-documented to be clinically efficient in severe asthma studies regarding its cost efficiency are scarce. Methods: Clinical and demographic features of subjects with severe allergic asthma who received omalizumab treatment for at least 1 year were documented before and after omalizumab treatment as well as pharmaceutical, emergency and hospital costs. Results: Clinical parameters of 22 subjects (mean age:50.7±12.4, male/female:12/10) involved in study and cost analysis of omalizumab treatment are given in tables 1 and 2 respectively. Conclusion: Omalizumab treatment is clinically effective and although it adds an extra pharmaceutical cost to the patients’ management it reduces the emergency and hospital costs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
